

# **Author Index** **Volume 51** **January-June 1995**

- Aboul-Oyoon, M., 355  
 Adolph, C., 303  
 Aleem, H.A., 355  
 Andolšek-Jeras, L., 75  
 Andrade, A., 87  
 Aso, T., 265  
 Back, D.J., 111  
 Baltaro, F., 293  
 Banharnsupawat, L., 225  
 Barbosa, I.C., 355  
 Bardin, C.W., 39, 141  
 Barnhart, K., 93  
 Barri, P., 87  
 Bassol, S., 201, 307  
 Batar, I., 87  
 Beier, S., 99  
 Benedetto, C., 13  
 Betrabet, S.S., 193  
 Bokström, H., 249  
 Bourinbaier, A.S., 319  
 Brandeis, A., 33  
 Buckshee, K., 237  
 Bundren, J.C., 209  
 Capuzzo, E., 293  
 Cekan, S.Z., 255  
 Chan, W.Y., 65  
 Charoenvisal, C., 225  
 Chatterjee, P., 237  
 Chauhan, S.C., 367  
 Chen, J.K., 167, 185  
 Chen, S.F., 167, 185  
 Chen, S.H., 167, 185  
 Chen, X.B., 167, 185  
 Cheng, H.Z., 167, 185  
 Chowdhury, S.R., 273  
 Coutinho, E.M., 355  
 Covelli, A., 13  
 Croxatto, H.B., 33  
 Czeizel, A.E., 19  
 d'Arcangues, C., 167, 185  
 Dantong, Y., 261  
 Datey, S., 155, 237  
 de Aloysio, D., 13  
 Delborge, W., 87  
 Deutsch, G., 83  
 Devoto, L., 93  
 Dhall, G.I., 237  
 Diaz, S., 33  
 Dong, Q.H., 167, 185  
 Donnez, J., 53  
 Düsterberg, B., 335  
 Dwivedi, A., 367  
 Egarter, Ch., 329  
 Elger, W., 99  
 Fang, K.J., 167, 185  
 Fanizza, G., 13  
 Farooq, A., 117  
 Farr, G., 289  
 Feldblum, P.J., 289  
 Ferrari, A., 293  
 Filippa, N., 221  
 Fotherby, K., 3  
 Fraser, I.S., 39, 243  
 Fritzemeier, K., 45  
 Fritzemeier, K.H., 131  
 Fuchs, N., 335  
 Fuhrmann, U., 45  
 Furman, I., 93  
 Gallina, D., 221  
 Gaur, L.N., 155, 237  
 Ge, J.L., 167, 185  
 Ge, R.S., 167, 185  
 Gennarelli, G., 13  
 Gordon, K., 265  
 Grandjean, P., 53  
 Grimes, D.A., 303  
 Gupta, N.K., 237  
 Hales, H.A., 149  
 Hall, P.E., 167, 185  
 Hannaford, P.C., 325  
 Hatasaka, H.H., 149  
 Hazra, M.N., 237  
 He, M.L., 167, 185  
 Hegele-Hartung, C., 131  
 Hernandez, C., 307  
 Ho, P.C., 347  
 Huber, J., 329  
 Hui, W.M., 87  
 Hümpel, M., 111  
 Jha, P., 117  
 Jiang, B.Y., 167, 185  
 Jones, K.P., 149  
 Jonsson, B., 255  
 Jung-Hoffmann, C., 341  
 Kaewsuk, O., 225  
 Kamboj, V.P., 367  
 Kaplan-Kraicer, R., 141  
 Kaushic, C., 203  
 Kodaj, I., 19  
 Kodkany, B.S., 237  
 Koetsawang, S., 225  
 Koopersmith, T.B., 197  
 Košmelj, K., 75  
 Krattenmacher, R., 99, 131

- Kuhl, H., 341  
Kuhnz, W., 111, 131  
Kuiwu, T., 261  
Kulkarni, R.D., 193  
Lacarra, M., 39  
Lähteenmäki, P., 33  
Lalitha, K., 237  
Landgren, B.-M., 255  
Lao, T., 347  
Lavenne, E., 53  
Lee-Huang, S., 319  
Leung, A., 215  
Li, M.X., 167, 185  
Lin, L., 59  
Linton, K.L.P., 303  
Liu, Y.X., 167, 185  
Lo, S.S.T., 231  
Lobo, R.A., 197  
Logambal, A., 237  
Louton, T., 111  
Luo, S.Y., 167, 185  
Luz de la Cruz, D., 307  
Ma, F.L., 167, 185  
Mainwaring, R., 149  
Manchanda, P., 237  
Martinez, F., 87  
Mauloni, M., 13  
Meehan, T.E., 283  
Mehta, S., 237  
Min-Xiang, L., 59  
Ming, H.D., 167, 185  
Mingzhang, S., 261  
Mishell, Jr., D.R., 1, 39  
Monaco, A., 293  
Moo-Young, A.J., 33  
Mühe, B., 335  
Muhn, P., 99  
Murugesan, K., 117  
Nanda, U.K., 237  
Nappi, R.E., 221  
Nava, M.P., 307  
Nelson, A.L., 299  
Ng, T.B., 65  
Ngai, S.W., 347  
Nicola, S., 293  
Norström, A., 249  
O'Dwyer, E., 355  
Patel, S.B., 193  
Pavez, M., 33  
Perotti, F., 221  
Peterson, C.M., 149  
Pizarro, E., 87  
Polatti, F., 221  
Poulson, A.M., 149  
Pullum, T.W., 59  
Punnahitanont, S., 225  
Putz, M., 329  
Qi, Z., 261  
Qing, Y.N., 167, 185  
RaiChoudhury, G., 237  
Rajaram, P., 237  
Ramos, D.E., 303  
Ray, R.M., 25  
Recio, R., 201  
Rivera, R., 279  
Rojnik, B., 75  
Rosenberg, M.J., 283  
Roy, M., 237  
Russell, P., 243  
Salzetti, R.G., 83  
Sang, G.W., 167, 185  
Saxena, B.N., 155, 193  
Saxena, N.C., 237  
Schiappacasse, V., 33  
Schillinger, E., 99  
Schlit, A.F., 53  
Schnepper, F.W., 83  
Sengupta, P.C., 237  
Shaaban, M.M., 355  
Shalgi, R., 141  
Shangchun, W., 87  
Shao, J.Y., 167, 185  
Shao, Q.X., 167, 185  
Shen, H.C., 167, 185  
Shi-Zhong, W., 59  
Shihata, A.A., 83  
Shirley, B., 209  
Singh, M.M., 273, 367  
Singhakovin, S., 225  
Sinha-Hikim, A., 215  
Sivaraman, R., 237  
Slater, E.P., 45  
Smith, C., 289  
Snow, R.C., 167, 185  
Song, S., 167, 185  
Speiser, P., 329  
Spence, A., 289  
Spinillo, A., 293  
Srivastava, S.R., 273  
Srivastava, U.K., 273  
Stevenson, K., 149  
Strohmer, H., 329  
Sumei, W., 261  
Sun, G.L., 167, 185  
Sun, H., 359  
Sutaria, U.D., 237  
Tang, G.W.K., 231  
Temmerman, M., 87  
Teng, C.S., 313  
Thiery, M., 87  
Thomas, D.B., 25  
Tiezzi, L., 351  
Toddywalla, V.S., 193  
Topo, K., 237  
Trivedi, R.N., 367  
Trossarelli, G.F., 13

- Trujillo, A.M., 307  
Upadhyay, S., 203  
Van der Pas, H., 87  
Van Kets, H., 87  
Van Trappen, Y., 87  
Vishwanath, P., 237  
Visness, C.M., 279  
Vrijens, M., 87  
Wang, C., 215  
Wang, I.Y.S., 243  
Wang, S.X., 167, 185  
Wang, X.Y., 167, 185  
Waugh, M.S., 283  
Weber-Diehl, F., 335  
Wei, Z.J., 121  
Weisberg, E., 39  
Wenzl, R., 329  
Westhoff, C., 351  
Wiegratz, I., 341  
Wieland, D., 351  
Wildemeersch, D., 87  
Williams, R.F., 265  
World Health Organization Collaborative Study of  
  Neoplasia and Steroid Contraceptives, 25  
Wu, S., 359  
Wu, S.C., 167, 185  
Xiao, B., 359  
Xiao, N., 359  
Xiao-Qing, C., 59  
Xiaoming, C., 87  
Yadav, S.C., 237  
Ye, B.L., 167, 185  
Ye, X., 121  
Ye, Z., 25  
Yeung, K.C.A., 347  
Yi, Q., 261  
Yu, J.Y., 167, 185  
Zamah, N.M., 111  
Zaveri, K., 237  
Zeng, T., 359  
Zepeda, A., 33  
Zhang, J.H., 167, 185  
Zhang, S.F., 167, 185  
Zhang, Z.Y., 167, 185  
Zhen, Q.S., 121  
Zhenjia, H., 261  
Zhi-Ping, G., 355  
Zhixin, W., 261  
Zhou, H.E., 167, 185  
Zhou, Z.Q., 167, 185  
Zhu, L.L., 167, 185  
Zhu, Z.R., 167, 185  
Zuan-chong, F., 87



# **Subject Index** **Volume 51** **January–June 1995**

- Abortifacient action, RU 486 (rat), 273
- Acrosin inhibitor, experimental vaginal contraceptive, 319
- Adolescent pregnancy, 303
- Anchored IUD, 87
- Androgen parameters,
  - effect of ethinylestradiol + gestodene, 341
  - effect of ethinylestradiol + norgestimate, 341
- Anordiol, effect on pregnancy (rat), 141
- Anordiol + RU 486, effect on pregnancy (rat), 141
- Antiestrogenic action, centchroman (rat), 367
- Antifertility effect,
  - anti-progestin CDB 2914 (male rat), 215
  - neem oil (rat), 203
- Anti-progestin CDB 2914, antifertility effect (male rat), 215
- Antiviral activity, guanidinobenzoates, 319
  
- Barrier contraceptive, non-spermicidal fit-free diaphragm, 289
- Biomedical studies, *Tripterygium wilfordii*, 121
- Bleeding patterns,
  - different contraceptive methods, 155
  - effect of progestin-only contraceptives, 149
  - monthly combined injectable contraceptives, 185
- Blood pressure, effect of ethinylestradiol + gestodene, 335
- Bone mass density, effect of ethinylestradiol + desogestrel, 221
- Breast milk, transfer of levonorgestrel, 193
- Breastfeeding and progestin-only pills, 279
- Breastfeeding women, use of progesterone-releasing vaginal rings, 255
  
- Candida vaginitis and OCs, 293
- Carbohydrate metabolism, effect of levonorgestrel, 197
- Carnitine level, vas deferens occlusion, 261
- CDB 2914, anti-progestin, 215
- Centchroman, antiestrogenic action (rat), 367
- Cervical carcinoma and depot-medroxyprogesterone acetate, 25
- Cervical collagen synthesis, effects of mifepristone and progesterone, 249
- Cervical dilatation,
  - gemeprost, 347
  - misoprostol, 347
- Climacteric symptoms, effect of ethinylestradiol + desogestrel, 13
- Clinical experience, ethinylestradiol + desogestrel, 3
- Clinical trial,
  - ethinylestradiol + desogestrel, 225
  - ethinylestradiol + gestodene, 225
  - Nestorone® subdermal implant, 33
  - progesterone-releasing vaginal rings, 255
- Coagulation factors, effect of oral contraceptives, 53
- Collagen synthesis, effects of mifepristone and progesterone, 249
- Combined oestrogen/progestogen contraceptive vaginal ring, 39
- Combined oral contraceptives, review of risks, 325
- Congenital limb deficiencies and oral contraceptives, 19
- Contraception postpartum, 75
- Contraceptive efficacy, monthly combined injectable contraceptives, 167
- Contraceptive methods, vaginal bleeding patterns, 155
- Copper-bearing IUDs, effect on endometrial morphometry, 243
  
- Depo-medroxyprogesterone acetate, 25, 149, 351
- Depressive symptoms, depot-medroxyprogesterone acetate users, 351
- Diaphragm, non-spermicide fit-free, 289
- Discontinuation, OC users, 283
- Drospirenone (ZK 30595), progestogenic activity, 99
- Dynein content, effect of gossypol (rat), 313
- Dysfunctional uterine bleeding, endometrial morphometric analysis, 243
  
- Embryonic development, effect of *Tripterygium wilfordii* (mouse), 65
- Endometrial morphometry, effect of copper-bearing IUDs, 243
- Estradiol cypionate + medroxyprogesterone acetate (Cyclofem), 167, 185, 307
- Estradiol valerate + 17-hydroxyprogesterone caproate (Injectable No. 1), 167, 185
- Estradiol valerate + norethisterone enanthate (Mesigyna), 167, 185, 307
- Ethinylestradiol + desogestrel, 3, 13, 221, 225, 329
- Ethinylestradiol + gestodene, 225, 335, 341
- Ethinylestradiol + levonorgestrel, 111, 355
- Ethinylestradiol + norethindrone acetate, 39
- Ethinylestradiol + norgestimate, 329, 341
  
- Fertility, following Norplant®-II implants, 237
  
- Gemeprost, 347
- Gestodene, receptor binding studies and trans-activation assays, 45

- Gossypol, effect on spermatogenesis (rat), 313  
Guanidinobenzoates, antiviral activity, 319  
GyneFix<sup>TM</sup> implant IUD, 87
- Hormonal profile, levonorgestrel-releasing IUD, 359
- Implant contraceptive,  
  levonorgestrel, 83, 149, 197, 237, 299  
  Nestorone<sup>TM</sup>, 33  
  norethindrone (monkey), 117  
  vaginal bleeding patterns, 155
- Implants removal, Norplant®, 83
- Inconsistent use, oral contraceptives, 283
- Induced abortions, social and demographic characteristics of women, 59
- Injectable contraceptive,  
  depo-medroxyprogesterone acetate, 25, 149, 351  
  estradiol cypionate + medroxyprogesterone acetate, 167, 185, 307  
  estradiol valerate + 17-hydroxyprogesterone caproate, 167, 185  
  estradiol valerate + norethisterone enanthate, 167, 185, 307  
  vaginal bleeding patterns, 155
- Insertion procedure, Norplant® implants, 299
- Insulin tolerance test, effect of levonorgestrel, 197
- Intrauterine device (IUD),  
  copper-bearing, 243  
  GyneFix<sup>TM</sup>, 87  
  releasing levonorgestrel, 231, 359  
  vaginal bleeding patterns, 155
- Intrauterine neem treatment (rat), 203
- IUD (see intrauterine device)
- Lactational amenorrhea method, family planning, 75
- Lactational anovulation, effect of nursing (monkey), 265
- Levonorgestrel,  
  effect on oocytes (mouse), 209  
  progestational activity (rat), 131  
  transfer to breast milk, 193
- Levonorgestrel IUD, 231, 359
- Levonorgestrel-oxime, progestational activity (rat), 131
- Male antifertility compounds, isolated from *Tripterygium wilfordii*, 121
- Menorrhagia, treatment with levonorgestrel IUD, 231
- Menses and spotting, sexual relations attitudes and practice, 93
- Menstrual pattern, levonorgestrel-releasing IUD, 359
- Metabolic parameters, effect of progestin-only contraceptives, 149
- Mifepristone (see RU 486)
- Misoprostol, 347
- Nafoxidine, antiestrogenic action (rat), 367
- Neem oil, antifertility effect (rat), 203
- Nestorone<sup>TM</sup> (ST 1435), progestin, 33
- Neutralizing pH of lidocaine, insertion of Norplant® implants, 299
- Non-spermicidal fit-free diaphragm, 289
- Nonoxynol-9 vaginal capsules, 201
- Norethindrone, 149
- Norethindrone subdermal implants (monkey), 117
- Norgestimate, progestational activity (rat), 131
- Norplant® subdermal implants, 83, 149, 197, 299
- Norplant®-II subdermal implants, 237
- Nursing, effect on lactational anovulation (monkey), 265
- OC pills, vaginal bleeding patterns, 155
- OCs and vulvovaginal candidiasis, 293
- Oocytes, effect of levonorgestrel (mouse), 209
- Oral contraceptive (OC),  
  discontinuation, 283  
  effect on coagulation factors, 53  
  ethinylestradiol + desogestrel, 3, 13, 221, 225, 329  
  ethinylestradiol + gestodene, 225, 335, 341  
  ethinylestradiol + levonorgestrel, 111  
  ethinylestradiol + norgestimate, 329, 341  
  levonorgestrel, 193  
  norethindrone, 149  
  review of risks, 325  
  use and misuse, 283
- Oral contraceptives and congenital limb deficiencies, 19
- Ovarian function,  
  effect of ethinylestradiol + desogestrel, 329  
  effect of ethinylestradiol + norgestimate, 329  
  levonorgestrel-releasing IUD, 359
- Ovulation return, injectable contraceptives, 307
- Pharmacodynamic effects, ethinylestradiol + desogestrel, 3
- Pharmacokinetics, levonorgestrel, 111
- Pharmacological characteristics, drospirenone (animal models), 99
- Pharmacological profile,  
  gestodene, 45  
  progestins, 45
- Postpartum, initiation of contraception, 75
- Pregnancy among teenagers, 303
- Progesterone, effect on cervical collagen synthesis, 249
- Progesterone-releasing vaginal rings, 255
- Progestin-only contraceptives, 149
- Progestin-only pills and breastfeeding, 279
- Progestogenic activity, drospirenone (animal models), 99
- Removal technique, Norplant® implants, 83
- Return of fertility, following Norplant®-II implants, 237
- Return of ovulation, injectable contraceptives, 307
- Reversible injection occlusion of vas deferens, 261

Risks, use of combined oral contraceptives, 325  
RU 486 (mifepristone),  
  abortifacient action (rat), 273  
  effect on cervical collagen synthesis, 249  
RU 486 + anordiol, effect on pregnancy (rat), 141

Safety of combined oral contraceptives, 325  
Sexual relations, during menses and spotting, 93  
Side effects, monthly combined injectable contraceptives, 167  
Spermatogenesis, effect of gossypol (rat), 313  
ST 1435 (Nestorone<sup>TM</sup>), progestin, 33  
Storage and temperature, effects on nonoxynol-9 vaginal capsules, 201

Tamoxifen, antiestrogenic action (rat), 367  
Tripterygium wilfordii,  
  biomedical studies, 121  
  effect on embryonic development (mouse), 65  
  isolated active compounds, 121

Unmarried women, induced abortions, 59

Vaginal bleeding, sexual relations attitudes and practice, 93  
Vaginal contraceptive,  
  acrosin inhibitor, 319  
  nonoxynol-9 capsules, 201  
Vaginal contraceptive pill, ethinylestradiol + levonorgestrel, 355  
Vaginal ring,  
  ethinylestradiol + norethindrone acetate, 39  
  releasing progesterone, 255  
Vas deferens occlusion, effect on carnitine level, 261  
Vitamin C, influence on pharmacokinetics of oral contraceptives, 111  
Vulvovaginal candidiasis and OCs, 293

Weight changes, effect of progestin-only contraceptives, 149